Dr. Reddy’s Labs Gets CDSCO Panel Nod to Manufacture, Market Semaglutide Injection We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Medical Bulletin 18/October/2025 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Comparable Cardiorenal Outcomes Among Three GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes: JAMA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Mediterranean Diet and Lifestyle Changes Cut Type 2 Diabetes Risk by 31 Percent: Study Finds We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
GLP-1 Drugs Linked to Higher Depression Risk but Lower Mortality, suggests research We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Type 1 diabetes increased among young people during the pandemic, reveals research We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
SGLT-2 diabetes drugs linked to lower risk of autoimmune diseases, suggests study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Researchers at Wayne State University and Johns Hopkins University are exploring the use of virtual reality (VR) to reduce stress in young adults suffering from diabetes. This research is being aided by a three-year grant in the amount of $941,418 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes…
Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for type 2 diabetes. Topline results from the ACHIEVE-2 trial showed orforglipron at a dose of 12 mg was better than AstraZeneca’s…
Medical Bulletin 15/October/2025 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link